<DOC>
	<DOCNO>NCT00887627</DOCNO>
	<brief_summary>A study compare conivaptan PK subject mild moderate kidney function impairment subject normal kidney function 48-hour continuous infusion conivaptan .</brief_summary>
	<brief_title>Study Compare Conivaptan Pharmacokinetics Subjects With Mild &amp; Moderate Kidney Function Impairment Subjects With Normal Kidney Function</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Conivaptan</mesh_term>
	<criteria>Weighs least 45 kg Body mass index 18 40 kg/m2 inclusive Must good health renal function impairment relate stable disease renal impaired subject Must screen predose estimate glomerular filtration rate ( GFR ) correspond level renal impairment base abbreviated Modification Diet Renal Disease ( MDRD ) formula Female subject childbearing potential must pregnant lactating , must negative pregnancy test , utilizes adequate contraceptive method study may surgically sterile and/or two year post menopausal Subject know HIV positive HIV antibody Has clinically significant history presence illness , medical condition , laboratory abnormality Is Hepatitis positive Subject renal impairment stable dose concomitant medication least 4 week prior start study and/or dose change likely study History substance abuse within 6 month prior screen Has clinically significant history presence psychiatric illness , malignancy , immunodeficiency syndrome Has abnormal liver function test ( ALT , AST , and/or bilirubin ) Has blood transfusion donated/lost 450ml blood within 56 day study drug administration donate plasma within 7 day prior study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Protein Binding</keyword>
	<keyword>Conivaptan</keyword>
	<keyword>Vaprisol</keyword>
	<keyword>Kidney Diseases</keyword>
</DOC>